Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

mpleted. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may resul
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asia-Pacific ... Analytics market in Asia-Pacific with analysis and forecast of ... million in 2014 to $208 million by 2019, at ... 2014 to 2019. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... 2014 According to market research ... WLAN Controllers; Wireless gateways)]- Global Advancements, Forecasts and ... global Outdoor Wi-Fi market with analysis and forecasting ... also identifies the drivers and the restrains for ... opportunities and challenges. , Browse 65 market data ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4
... N.J., Dec. 31 Pharmasset, Inc.,(Nasdaq: VRUS ... developing and commercializing novel drugs to treat viral,infections, ... ended,September 30, 2007. Pharmasset reported a net loss ... per share, as compared to a net loss,attributable ...
... GATOS, Calif., Dec. 31 Three Palm ... that it has received 510(k) clearance,from the ... its WorkstationOne(TM),Breast Imaging Workstation. WorkstationOne is intended ... images, and was developed with,the goal of ...
... (NYSE: MYL ) today,announced that Mylan Pharmaceuticals ... and Drug Administration (FDA) for its Abbreviated New ... Balsalazide Disodium Capsules are the generic version ... of approximately,$130.9 million for the 12 months ending ...
Cached Biology Technology:Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
(Date:10/15/2014)... biophysics textbook and it describes how life functions and ... into biological systems and provides an understanding of the ... how our genes make proteins that control the dynamics ... an organism. It quantifies the principles of life and ... on both large and small scales. The book is ...
(Date:10/15/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD and ... the growing mobile commerce market releases photos and video of the ... Monday October 13 th . Gino Pereira ... and angel investor Mr. Chad A. Verdi rang the ... thanked his investors and employees "for their work and dedication in ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... Institute of New York University (NYU-Poly) and the NYU ... their lab that is five times more efficient in ... vectors. This novel complex is a peptide-polymer hybrid, assembled ... to carry DNA into cells. Results of ...
... The same tiny cellulose crystals that give trees and ... now been shown to have the stiffness of steel. ... new class of biomaterials with wide-ranging applications, such as ... precise models based on the atomic structure of cellulose ...
... Supramolecular chemistry, aka chemistry beyond the molecule, in ... by non-covalent bonds, is just beginning to come ... Metal-organic frameworks (MOFs) are commanding much of the ... but a new player has joined the field ...
Cached Biology News:Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells 2Cellulose nanocrystals possible 'green' wonder material 2Cellulose nanocrystals possible 'green' wonder material 3SOFS take to water 2SOFS take to water 3
... The MX80 Series of positioning ... linear motor, ballscrew, leadscrew, micrometer, and ... construct high performance, cost-effective multi-axis systems. ... cross-roller bearings, encoder resolutions down to ...
...
... negatively supercoiled DNA in presence of EDTA ... of supercoiling on transcription in vitro , ... the degree of supercoiling of naturally occurring DNA ... length by only one base-pair , Increasing ...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
Biology Products: